What it's for (Indications)
- Chloroquine, a 4-aminoquinoline derivative, is indicated for the treatment and prophylaxis of malaria caused by susceptible strains of *Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale*, and *Plasmodium malariae*.
- It is important to note that chloroquine resistance is widespread, particularly for *P.
- falciparum* in many endemic areas, and local susceptibility patterns must be considered meticulously prior to initiation of therapy.
- Therefore, its use for malaria must be guided by current epidemiological data and national or international treatment guidelines.
- Furthermore, chloroquine is also indicated for the treatment of extra-intestinal amoebiasis, such as amebic liver abscess, where it serves as an effective agent against the trophozoite forms of *Entamoeba histolytica* in hepatic and other extra-intestinal tissues.
- While historically employed for certain autoimmune conditions like rheumatoid arthritis and systemic lupus erythematosus due to its immunomodulatory properties, these applications are now less common, often superseded by hydroxychloroquine or other therapeutic agents with more favorable safety profiles or specific patient indications.
- Its primary contemporary utility remains firmly within the antimalarial and amebicidal contexts, requiring careful clinical judgment to ensure both efficacy and paramount patient safety.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Chloroquine dosage regimens are highly individualized and contingent upon several critical factors, including the specific indication (e.g., malaria treatment versus prophylaxis, or amoebiasis), the patient's age and body weight, the geographical prevalence of chloroquine-resistant malaria strains, and the patient's renal and hepatic function. For the acute treatment of susceptible malaria, a typical adult regimen involves an initial loading dose of chloroquine base, followed by subsequent maintenance doses administered over a 2-3 day period, generally aiming for a total cumulative dose of approximately 25 mg/kg of chloroquine base. Pediatric dosing is precisely calculated based on body weight to ensure therapeutic drug concentrations while rigorously minimizing the risk of toxicity. For malaria prophylaxis, a standardized weekly dose is usually administered, commencing prior to entering an endemic area and continuing for a defined period (typically 4-8 weeks) after departing. In the treatment of extra-intestinal amoebiasis, a distinct daily dosing schedule is employed, typically for a duration ranging from several days to several weeks. Intravenous administration of chloroquine is reserved exclusively for cases of severe or complicated malaria where oral therapy is infeasible, necessitating meticulous titration and continuous monitoring due to the potential for rapid systemic absorption and an elevated risk of cardiotoxicity. All dosing decisions must be made by a qualified healthcare professional, strictly adhering to established clinical guidelines and individual patient specificities. |
Safety & Warnings
Common Side Effects
- Chloroquine therapy can be associated with a broad spectrum of adverse effects, encompassing both common and less frequent but potentially severe manifestations.
- Gastrointestinal disturbances are common, including nausea, vomiting, diarrhea, and abdominal cramps.
- Neurological effects such as headache, dizziness, and lightheadedness are also frequently reported.
- Ocular disturbances, particularly blurred vision and difficulties with accommodation, are common and warrant careful attention, especially with prolonged use.
- Less common but significantly more serious adverse events include retinopathy, which is a critical concern due to its potential to cause irreversible vision loss and is predominantly associated with prolonged exposure or high cumulative doses.
- Cardiotoxicity can manifest as QTc interval prolongation, T-wave abnormalities, and, in severe instances, life-threatening ventricular arrhythmias (e.
- g.
- , Torsades de Pointes) or cardiomyopathy.
- Neuropsychiatric effects, such as anxiety, confusion, hallucinations, psychosis, and seizures, have been reported.
- Hematological abnormalities, including agranulocytosis, aplastic anemia, and hemolytic anemia (particularly in individuals with glucose-6-phosphate dehydrogenase deficiency), may occur.
- Dermatological manifestations include pruritus (a common and often intense complaint, particularly in individuals with darker skin pigmentation), various skin rashes, alopecia, and epidermal pigmentation changes.
- Other recognized adverse reactions include ototoxicity, myopathy, and severe hypoglycemia, underscoring the necessity for comprehensive patient assessment and vigilant monitoring throughout the entire course of treatment.
Serious Warnings
- Black Box Warning: ***SERIOUS WARNINGS REGARDING POTENTIAL FOR SEVERE AND IRREVERSIBLE ADVERSE EFFECTS*** Chloroquine use is associated with a risk of severe and potentially irreversible adverse effects that necessitate careful patient selection, rigorous monitoring, and thorough consideration of alternative therapeutic options. **1. Ocular Toxicity (Retinopathy):** Prolonged administration of chloroquine, particularly at higher daily doses or with increased cumulative doses, carries a significant and well-documented risk of causing irreversible retinal damage (chloroquine retinopathy). This can lead to permanent and profound vision loss, which may progress even after drug discontinuation. Comprehensive baseline and regular periodic ophthalmologic examinations, including precise visual field testing (e.g., 10-2 Humphrey visual field) and fundoscopy, are mandatory for all patients on long-term therapy or those receiving higher doses, and should be performed more frequently in patients with risk factors such as renal impairment, advanced age, or concomitant use of tamoxifen. Discontinuation of chloroquine should be considered immediately if any visual disturbances or objective retinal changes are detected. **2. Cardiotoxicity:** Chloroquine can induce dose-dependent cardiotoxicity, including significant QTc interval prolongation, T-wave abnormalities, and an increased risk of serious ventricular arrhythmias, such as Torsades de Pointes, which can be life-threatening and potentially fatal. Cases of cardiomyopathy, some leading to fatal outcomes, have also been reported with prolonged use. Chloroquine should be used with extreme caution and under close cardiac supervision in patients with pre-existing cardiac disease, congenital or acquired QTc prolongation, a history of arrhythmias, or in conjunction with other QTc-prolonging medications. Baseline and regular electrocardiographic (ECG) monitoring is strongly recommended to identify and manage these risks. **3. Neuropsychiatric Events:** Chloroquine has the potential to precipitate or exacerbate severe neuropsychiatric adverse reactions, including but not limited to psychosis, suicidal ideation, depression, anxiety, agitation, hallucinations, and seizures. Caution should be exercised when prescribing chloroquine to patients with a history of psychiatric disorders, epilepsy, or other neurological conditions. Patients and caregivers must be thoroughly educated and advised to report any new or worsening neuropsychiatric symptoms or behavioral changes immediately to their healthcare provider. The potential for these severe adverse effects underscores the critical importance of a thorough risk-benefit assessment and close clinical supervision throughout the entire course of chloroquine therapy.
- Several critical warnings are associated with chloroquine use, mandating careful patient selection, thorough pre-treatment evaluation, and rigorous ongoing monitoring.
- **Ocular Toxicity:** The most paramount warning is the potential for irreversible retinal damage (chloroquine retinopathy), which can lead to permanent and profound vision loss.
- The risk significantly increases with higher daily doses, longer durations of treatment, and higher cumulative dosages.
- Comprehensive baseline and regular periodic ophthalmologic examinations, including visual acuity, visual fields (e.
- g.
- , 10-2 Humphrey visual field testing), and fundoscopy, are absolutely crucial for all patients on long-term therapy or those receiving higher doses, and should be performed more frequently in patients with renal impairment or other risk factors.
- Discontinuation of chloroquine should be immediately considered if any visual disturbances or objective retinal changes are detected.
- **Cardiotoxicity:** Chloroquine can induce dose-dependent cardiotoxicity, manifesting as QTc prolongation, T-wave inversion, and an elevated risk of serious ventricular arrhythmias, potentially culminating in cardiac arrest.
- Cases of cardiomyopathy, sometimes fatal, have also been reported with prolonged use.
- Extreme caution is advised in patients with pre-existing cardiac disease, congenital or acquired QTc prolongation, a history of arrhythmias, or those concurrently using other QTc-prolonging medications.
- Baseline and periodic electrocardiograms are strongly recommended.
- **Neuropsychiatric Effects:** Chloroquine has the potential to induce or exacerbate severe neuropsychiatric disorders, including anxiety, depression, psychosis, suicidal ideation, hallucinations, and seizures.
- Therefore, caution is advised when prescribing chloroquine to patients with a history of epilepsy or psychiatric conditions.
- Patients and caregivers must be educated to report any new or worsening neuropsychiatric symptoms promptly.
- **Hypoglycemia:** Chloroquine can cause severe hypoglycemia, sometimes resulting in unconsciousness or coma, even in patients without diabetes.
- Blood glucose levels should be routinely monitored.
- **Hematologic Toxicity:** Rare but serious cases of blood dyscrasias, such as aplastic anemia and agranulocytosis, have been reported.
- Use with caution in patients with pre-existing bone marrow suppression.
- **G6PD Deficiency:** Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at an increased risk of hemolytic anemia.
- **Exacerbation of Psoriasis and Myasthenia Gravis:** Chloroquine can exacerbate these pre-existing conditions.
- Its use during pregnancy and lactation should only occur when the potential benefits clearly outweigh the potential risks, particularly for life-threatening malaria infections in endemic areas.
How it Works (Mechanism of Action)
Chloroquine's primary mechanism of action as an antimalarial agent is intricately linked to its interference with the detoxification processes of heme within the intraerythrocytic *Plasmodium* parasite. As a weak base, chloroquine readily diffuses across biological membranes, concentrating specifically within the highly acidic food vacuole of the parasite, where it becomes protonated ('ion-trapped'). Within this acidic environment, the parasite actively digests host hemoglobin to acquire amino acids, a process that releases free heme, which is profoundly toxic to the parasite. To neutralize this toxicity, the parasite normally polymerizes the free heme into a non-toxic, insoluble crystalline pigment called hemozoin (also known as malaria pigment). Chloroquine effectively binds to and forms a complex with free heme, thereby preventing its polymerization into hemozoin. This inhibition leads to an accumulation of free, unpolymerized, and highly toxic heme species within the parasite's food vacuole. These toxic heme compounds then damage critical parasite membranes, generate deleterious oxidative stress, and inhibit essential parasitic enzymes, ultimately leading to the demise of the parasite. For its historical immunomodulatory effects in conditions such as rheumatoid arthritis and systemic lupus erythematosus, chloroquine acts as a lysosomotropic agent, increasing the pH within the lysosomes and endosomes of various immune cells. This elevated pH impairs antigen processing and presentation, modulates the signaling pathways of toll-like receptors (TLRs), particularly TLR9, and inhibits the production of pro-inflammatory cytokines, thereby dampening aberrant immune responses.